

## CLAIM AMENDMENTS

Claims 1 through 19 (canceled).

1           Claim 20 (currently amended) Recombinant poxvirus  
2 comprising in the viral genome at least two expression cassettes,  
3 each comprising ~~[[the]]~~ a cowpox ATI promoter according to SEQ ID  
4 NO:1, a polynucleotide sequence in which not more than 6  
5 nucleotides are substituted, deleted, and/or inserted into SEQ ID  
6 No:1 and still active as an ATI promoter, or a polynucleotide  
7 comprising at least 10 nucleotides including nucleotides 22 to 29  
8 of SEQ ID No: 1 and still active as an ATI promoter or a derivative  
9 ~~thereof or a subsequence of the ATI promoter or the derivative~~  
10 thereof and a coding sequence, wherein the expression of the coding  
11 sequence is regulated by said promoter or said polynucleotides 7  
12 ~~derivative or subsequence and wherein the derivative of the cowpox~~  
13 ~~ATI promoter is a sequence that has a homology of at least 60% when~~  
14 ~~compared to the sequence of SEQ ID.: No. 1 and/or a sequence in~~  
15 ~~which not more than 6 nucleotides are substituted, deleted and/or~~  
16 ~~inserted in the sequence of SEQ ID.: No. 1, wherein the subsequence~~  
17 ~~of the ATI promoter has a length of at least 10 nucleotides of the~~  
18 ~~sequence of SEQ ID.: No. 1 and wherein the promoter, derivative or~~  
19 ~~subsequence has the biological activity of being active as a~~  
20 promoter.

1 Claim 21 (currently amended) Recombinant poxvirus  
2 according to claim 20, wherein the Cowpox ATI promoter ~~, derivative~~  
3 ~~or subsequence~~ has the biological activity of being active as a  
4 Vaccinia virus late promoter.

1 Claim 22 (currently amended) Recombinant poxvirus  
2 according to claim 20, wherein the Cowpox ATI promoter is SEQ ID  
3 No: 1 or a promoter, derivative or subsequence polynucleotide which  
4 comprises at least 10 nucleotides including nucleotides 25 to 29 or  
5 22 to 29 of SEQ ID No:1 and still active as an ATI promoter.

1 Claim 23 (currently amended) Recombinant poxvirus  
2 according to claim 20, wherein the Cowpox ATI promoters in each  
3 expression cassette, derivatives or subsequences in the recombinant  
4 poxvirus are the same identical to one another.

1 Claim 24 (previously presented) Recombinant poxvirus  
2 according to claim 20, wherein at least two expression cassettes  
3 are inserted into the same insertion site in the poxvirus genome.

1 Claim 25 (currently amended) Recombinant poxvirus  
2 according to claim 20, wherein the Cowpox ATI promoter in at least  
3 one of the expression cassettes has the sequence of SEQ ID.: No. 1.

1 Claim 26 (currently amended) Recombinant poxvirus  
2 according to claim 20, wherein the Cowpox ATI promoter in ~~at least~~

3 ~~one of the expression cassettes is a derivative of the ATI promoter~~  
4 ~~or a subsequence of the ATI promoter or a derivative thereof~~ has  
5 the sequence of SEQ ID.: No. 1.

1       Claim 27 (previously presented) Recombinant poxvirus  
2 according to claim 20, wherein the poxvirus is selected from the  
3 group consisting of orthopoxviruses and avipoxviruses.

1       Claim 28 (previously presented) Recombinant poxvirus  
2 according to claim 27, wherein the orthopoxvirus is a vaccinia  
3 virus and wherein the avipoxvirus is selected from the group  
4 consisting of canarypoxvirus and fowlpoxvirus.

1       Claim 29 (previously presented) Recombinant poxvirus  
2 according to claim 28, wherein the vaccinia virus is modified  
3 vaccinia virus strain Ankara (MVA), in particular MVA-BN and MVA  
4 575, deposited under numbers V00083008 and V00120707, respectively,  
5 at the European Collection of Animal Cell Cultures (ECACC).

1       Claim 30 (previously presented) Recombinant poxvirus  
2 according to claim 29, wherein at least one of the expression  
3 cassettes is inserted in a naturally occurring deletion site of the  
4 MVA genome with respect to the genome of the vaccinia virus strain  
5 Copenhagen.

1           Claim 31 (previously presented) Recombinant poxvirus  
2 according to claim 20, wherein at least one of the expression  
3 cassettes is inserted in an intergenic region of the poxvirus  
4 genome.

1           Claim 32 (previously presented) Recombinant poxvirus  
2 according to claim 20, wherein at least one of the coding sequences  
3 codes for at least one antigen, antigenic epitope, and/or a  
4 therapeutic compound.

Claim 33 (canceled)

1           Claim 34 (previously presented) Vaccine or  
2 pharmaceutical composition comprising a recombinant poxvirus  
3 according to claim 20.

Claim 35 (canceled)

1           Claim 36 (withdrawn) Method for introducing coding  
2 sequences into target cells comprising the infection of the target  
3 cells with the virus according to claim 20.

1           Claim 37 (withdrawn) Method for producing a peptide,  
2 protein and/or virus comprising:

3           a) infection of a host cell with the recombinant poxvirus  
4 according to claim 20,

5           b) cultivation of the infected host cell under suitable  
6 conditions, and

7           c) isolation and/or enrichment of the peptide and/or  
8 protein and/or viruses produced by said host cell.

1           Claim 38 (withdrawn) Method for effecting an  
2 immunological response in a living animal host including a human  
3 comprising administering the virus according to claim 20 to the  
4 animal or human to be treated.

1           Claim 39 (withdrawn) Method according to claim 38  
2 comprising the administration of at least  $10^2$  TCID<sub>50</sub> (tissue culture  
3 infectious dose) of the virus.

1           Claim 40 (withdrawn) A cell containing the virus  
2 according to claim 20.

1           Claim 41 (previously presented) A method for the  
2 production of a recombinant virus according to claim 20 comprising  
3 the step of inserting at least two expression cassettes into the  
4 genome of a poxvirus.

1           Claim 42 (withdrawn) Method for effecting an  
2 immunological response in a living animal host, including a human,  
3 comprising administering the composition or vaccine according to  
4 claim 34 to the animal or human to be treated.